TITLE

Mayo Clinic Consensus Recommendations for the Depth of Excision in Primary Cutaneous Melanoma

AUTHOR(S)
GROTZ, TRAVIS E.; MARKOVIC, SVETOMIR N.; ERICKSON, LORI A.; HARMSEN, WILLIAM S.; HUEBNER, MARIANNE; FARLEY, DAVID R.; POCKAJ, BARBARA A.; DONOHUE, JOHN H.; SIM, FRANKLIN H.; GRANT, CLIVE S.; BAGARIA, SANJAY P.; SHIVES, THOMAS C.; BALCH, CHARLES M.; JAKUB, JAMES W.
PUB. DATE
June 2011
SOURCE
Mayo Clinic Proceedings;Jun2011, Vol. 86 Issue 6, p522
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Currently, no data from randomized controlled clinical trials are available to guide the depth of resection for Intermediate-thickness primary cutaneous melanoma. Thus, we hypothesized that substantial variability exists in this aspect of surgical care. We have summarized the literature regarding depth of resection and report the results of our survey of surgeons who treat melanoma. Most of the 320 respondents resected down to, but did not include, the muscular fascia (extremity, 71%; trunk, 66%; and head and neck, 62%). However, significant variation exists. We Identified variability in our own practice and have elected to standardize this common aspect of routine surgical care across our institution. In light of the lack of evidence to support re section of the deep muscular fascia, we have elected to pre- serve the muscular fascia as a matter of routine, except when a deep primary melanoma or thin subcutaneous tissue dictates otherwise.
ACCESSION #
62094796

 

Related Articles

  • “Rosary of Testes”: Splenogonadal Fusion in Association with Bilateral Abdominal Testes Presenting as Polyorchidism. Shadpour, Pejman; Rezaimehr, Behkam // Case Reports in Urology;11/29/2015, p1 

    Polyorchidism is a rare anomaly where early segmentation in the gonadal ridge can lead to the development of three or less commonly four testes in one individual. Just over 150 reports of this phenomenon exist in English medical literature. However, once confronted by the clinical finding of...

  • Therapy Moves to Phase III. Reiman, Patty // Dermatology Times;Feb2003, Vol. 24 Issue 2, p24 

    Focuses on the results of the clinical trial conducted on the effectiveness of a combination vaccine used to treat metastatic melanoma in Detroit, Michigan. Comparison between biochemotherapy and immunotherapy; Importance of melacine in promoting prolonged disease stability; Combination of...

  • What can we learn from phase II adjuvant trials in melanoma? Keilholz, U; Suciu, S; Eggermont, A M M // British Journal of Cancer;7/1/2000, Vol. 83 Issue 1, p6 

    Editorial. Focuses on the study related to clinical trial of treatment of melanoma patients in second and fourth stages. Situation at the time the trial was instituted; Type of conclusions that is possible from an adjuvant non-randomized phase second clinical trial; Things that can be learnt...

  • Melanoma targets.  // Nature Reviews Cancer;Jul2011, Vol. 11 Issue 7, p463 

    The article discusses three clinical trials for enhancing the treatment of melanoma.

  • Research & Markets: Melanoma Global Clinical Trials Review Q4 2010.  // Biomedical Market Newsletter;3/31/2011, p603 

    The article reports on the addition of GlobalData's new report titled "Melanoma Global Clinical Trials Review, Q4 2010" which provides information and data concerning on the clinical trials on melanoma.

  • Shorter, high-dose interferon regimen feasible for stage III melanoma patients. McKnight, Whitney; Cowles, Carey // Hem/Onc Today;8/10/2011, Vol. 12 Issue 15, p1 

    The article reports on the results of a clinical trial presented by Vanna Chiarion-Sileni at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois which indicate that a shorter, high-dose interferon regime is feasible for stage III melanoma patients.

  • Immunotherapeutic did not meet co-primary endpoint in study.  // Hem/Onc Today;11/25/2013, Vol. 14 Issue 22, p64 

    The article focuses on the announcement by healthcare company GlaxoSmithkline that its phase 3 trial which evaluated the efficacy and safety of the protein melanoma-associated antigen-A3 (MAGE-A3) immunotherapeutic did not meet its first co-primary endpoint of significantly extending...

  • G 3139: Augmerosen, Bcl-2 Antisense Oligonucleotide - Genta, GC 3139, Genasense.  // Drugs in R&D;2002, Vol. 3 Issue 1, p44 

    Adis CommentsG 3139 [GC 3139; Genasenseâ„¢, BCL2 antisense oligonucleotide, augmerosen] is an antisense oligonucleotide developed by Genta in the USA. It is targeted towards the Bcl-2 protein, which is a potent inhibitor of apoptosis and is overexpressed in many cancers including, follicular...

  • Melanoma vaccines show promise. Josefson, Deborah // BMJ: British Medical Journal (International Edition);03/14/98, Vol. 316 Issue 7134, p800 

    Details the clinical trials for vaccines developed to fight melanoma. Procedure used in the trials; Findings of the trials.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics